Pfizer Corporation

Flatley Discovery Lab, LLC

Michael Paul Zawistoski

Bruce A Lefker

Philip Albert Carpino

Bridget McCarthy Cole

Judith L Treadway

Charles Kwok-Fung Chiu

Lydia Codetta Pan

Richard Allen Nugent

Yevgen Barsukov

Kimberly O Cameron

Paul Andrew Dasilva-Jardine

Robert F Day

Richard Chesworth

Asmita Deshpande

The invention relates to a compound of Formula I or IA compositions comprising compounds of Formula I or IA, and methods of treating cystic fibrosis comprising the step of administering a therapeutically effective amount of a compound of Formula I or IA to a patient in need thereof: 

Compounds and methods for the treatment of cystic fibrosis

The invention relates to a compound of Formula I and methods of treating cystic fibrosis comprising the step of administering a therapeutically effective amount of a compound of Formula I or IA to a patient in need thereof. 

The invention relates to a compound of Formula I and methods of treating CFTR (cystic fibrosis transmembrane conductance regulator) mediated diseases, in particular cystic fibrosis, comprising the step of administering a therapeutically effective amount of a compound of Formula I or IA to a patient in need thereof: 

This invention is directed to methods of treating insulin resistance in a mammal which comprise administering an effective amount of a compound of formula I,where the variables are defined in the specification, or the stereoisomeric mixtures, diastereomerically enriched, diastereomerically pure, enantiomerically enriched or enantiomerically pure isomers, or the pharmaceutically acceptable salts and prodrugs thereof to said mammal. The compounds of formula I are growth hormone secretagogues and as such are useful for increasing the level of endogenous growth hormone. In another aspect this invention provides certain intermediates which are useful in the synthesis of the foregoing compounds and certain processes useful for the synthesis of said intermediates and th compounds of formula I. This invention is further directed to methods comprising administering to a human or other animal a combination of a functional somatostatin antagonist such as an alpha-2 adrenergic agonist and a compound of formula I.

Treatment of insulin resistance

Treatment of insulin resistance with growth hormone secretagogues

This invention relates to compounds useful for treating or preventing obesity, breast cancer, osteoporosis, endometriosis, cardiovascular disease, prostatic disease, and the like, and to pharmaceutical composition, methods, and kits comprising such compounds.

Tetrahydroisoquinoline compounds as estrogen agonists/antagonists

Growing community of inventors

West Warwick, RI, United States of America

Michael Paul Zawistoski